OGT is excited to connect with the cancer genomics community at the CGC 2025 Annual Meeting, August 3–6 in Houston, TX. Visit us at booth #26 to explore our full portfolio of CytoCell® FISH probes, CytoSure® arrays, and SureSeq™ NGS panels—powerful tools for gaining clear

💡 We're excited to share Laura Semenuk’s (Queen’s University, Canada) GLGC conference presentation on her implementation of a custom NGS SureSeq myPanel™, the Somatic Myeloid Lymphoid Panel. Watch Laura’s presentation: ogt.com/resources/ngs-…

We're here at the CGC 2025 Annual Meeting in Houston, TX! Visit our experts at booth #26 to explore our full portfolio of CytoCell® FISH probes, CytoSure® arrays and SureSeq™ NGS panels, which give you clear insights into hematological malignancies and more. Don’t miss our

Interested in reducing your lab’s FISH analysis time by up to 60%? In this presentation from ACGS 2025, OGT expert Chris Harrigan demonstrates how ASI’s HiBand system can streamline a lab’s cytogenetic workflows and deliver improved efficiency with AI-based karyotyping:

Here at OGT, we proudly stand in support of Blood Cancer Awareness Month. Every brave step in the fight against blood cancer matters. By spreading awareness, we hope we can help highlight the importance of cancer research now more than ever. Stay tuned for more information on

OGT and QIAGEN announce partnership that unlocks a complete sample to report workflow for SureSeq™ NGS panels. Through this partnership, SureSeq NGS panel users can gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to

OGT is proud to announce that the U.S. Food and Drug Administration (U.S. FDA) has granted their De Novo Classification Request for the CytoCell® KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor. This decision by the

Today our colleagues at OGT proudly wear red and yellow to show our support for all individuals and their families in each of their journeys against blood cancer. ❤️ Red symbolises blood cancer 💛 Yellow symbolises childhood leukaemia, sarcoma and bone cancer Show your

As part of our mission to raise awareness about blood cancer, we end this month with a blood cancer quiz! Increase your knowledge about blood cancer by taking our quiz today: surveymonkey.com/r/5S3FQS7 #BloodCancerAwarenessMonth

Attending the CAGC & CCMG Joint Annual Scientific Meeting? 🇨🇦 Come find us at booth #22 and discuss the genomic solutions and insights you need with OGT expert Michel Viau. #CAGCCCMG2025

30 years of innovation. 30 years of impact. 🙌 Follow us we celebrate 30 years of OGT! 🎉 Since 1995, OGT has grown, evolved and built enduring partnerships. This milestone reflects our team’s dedication, innovation and passion that has made three decades of excellence

Recently, our OGT expert Rich Evans, visited the National Reference Lab team in Abu Dhabi 🇦🇪. During the visit, Rich provided his insight into potential analysis strategies for new CytoCell® probes the lab is implementing. A big thank you to the Abu Dhabi team for a successful

We are excited to be attending the AMP 2025 Annual Meeting and Expo in Boston, Massachusetts in a few weeks! 🇺🇸 Visit us at booth #1028 where our experts will be available to talk about our range of SureSeq™ NGS panels, CytoCell® FISH probes and CytoSure® arrays, which give

Measurable residual disease (MRD) has become an important biomarker in both research and clinical settings for several haematological malignancies, including acute myeloid leukaemia (AML). In AML, MRD is used for its value in prognostic, predictive, monitoring, and

📰 The latest edition of our DNA Dispatch newsletter has arrived! This edition includes exciting news on our new bioinformatics collaboration with Qiagen. View now: ogt.com/resources/dna-… #dnadispatch #ogtnews #ogtnewsletter

Dive deeper into AML biomarkers with the new SureSeq™ Myeloid MRD Plus NGS Panel, our latest innovation in NGS solutions for haematological malignancies. Why your lab should start using the SureSeq Myeloid MRD Plus NGS Panel: 🧬 An unparalleled bait design and sequence

🔬 Advancing AML MRD Detection at #AMPath2025 We're excited to announce OGT’s must-attend workshop featuring Sean Glenn, PhD from Roswell Park Comprehensive Cancer Center at AMP 2025. "Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study" 📅